Ehlers-Danlos Is Not a Trend. It Is a Body Type.

Here is the fact that ends the “is this a fad” argument for me.

Textbooks quoted Ehlers-Danlos syndrome at about 1 in 5,000 people. Then researchers in Wales did something simple and enormous: they pulled 27 years of real medical records — every family doctor visit and every hospital admission in an entire national health system — and just counted. They found that roughly 1 in 500 people carried a diagnosis of Ehlers-Danlos syndrome or joint hypermobility syndrome.¹

Ten times more common than we were taught. And that is only the people who had already been diagnosed. Everyone still walking around undiagnosed is not in that number.

Nobody’s connective tissue changed between 1990 and today. What changed is that we started looking, and we finally had a name to write down.

Four things happened at roughly the same time, and together they look like a trend when they are really a correction.

1. The name kept moving. What we now call hypermobile Ehlers-Danlos syndrome has been called benign joint hypermobility syndrome, joint hypermobility syndrome, EDS type III, and EDS hypermobility type. Every rename scattered the research and reset the count. You cannot track a condition that changes its name every fifteen years.

2. The word “benign” did real damage. For decades the label itself told doctors not to worry about it. Patients were flexible, so they were fine. The pain, the fatigue, the fainting, the stomach problems — those got sorted into other piles, or into no pile at all.

3. In 2017, the field finally agreed on definitions. An international group published a classification that sorted Ehlers-Danlos syndrome into 13 subtypes with written criteria, and created a companion category called hypermobility spectrum disorder for people who are clearly affected but do not check every box.² Once you can define something, you can diagnose it, study it, and bill for it.

4. Patients found each other. Yes, social media is part of this story — and that is not the scandal people think it is. Someone with twenty unrelated symptoms and fifteen normal test results saw a stranger describe her exact life, brought it to a doctor, and turned out to be right. That is not a fad. That is what happens when a real pattern finally gets a shared vocabulary.

Self-diagnosis is not diagnosis, and I will say that plainly. But “I read about this online” is a reason to examine someone carefully, not a reason to dismiss them. We wrote a full walkthrough of how a real diagnosis is made in our HSD and EDS diagnosis roadmap.

Ehlers-Danlos syndrome is a group of inherited conditions that affect connective tissue — the material your body is built out of. Connective tissue is the rope, the tape, and the packing material all at once. It is your ligaments, your tendons, your skin, your blood vessel walls, your gut walls, and the fascia that wraps and connects every one of them.

Most of that material is built from collagen. Think of collagen as rebar. If the rebar in a building is slightly off-spec, you do not get one broken wall. You get a building that flexes in a hundred small ways under normal load.

That is the single most important idea on this page. Loose joints are the symptom that is easy to see. They are not the disease. The same material that lets a shoulder slide also lines the blood vessels that are supposed to squeeze when you stand up, and the gut that is supposed to move food along, and the fascia that is supposed to give your nervous system a clear signal about where your body is in space.

This is why I keep using the phrase body type instead of disease. A hypermobile body is not a normal body that broke. It is a body built to a different spec, running in a world designed around the standard one. Our main site goes deeper on that framing in Hypermobility, HSD & hEDS: A Body Type That Needs Care.

The 2017 international classification recognizes 13 subtypes of Ehlers-Danlos syndrome.² Almost all of them are genuinely rare, and almost all of them can be confirmed with a blood test that looks for a specific gene change. A few you should know by name:

That last bullet causes enormous confusion, so let me be blunt about it. A negative genetic panel does not rule out hypermobile EDS. It rules out the other twelve subtypes. Patients are told “your genetic testing was normal, so you don’t have EDS” constantly, and it is one of the most common errors I correct in clinic.

And we now have good evidence that the clinical diagnosis holds up. The HEDGE study — the largest genetic study of hypermobile EDS ever run, with 1,000 participants from 86 countries whole-genome sequenced at the Broad Institute — re-reviewed every enrolled case and found the original clinical diagnosis was correct in more than 99% of them.³ Doctors examining patients carefully were getting it right. What the study did not find was a single gene. hEDS looks like it involves many rare variants interacting, which is exactly why a one-gene test does not exist yet.

Hypermobility spectrum disorder (HSD) is the label for someone who has symptomatic hypermobility but does not meet every item on the hEDS checklist. It was created in 2017 for a good reason: before it existed, those patients got nothing at all.

But I want to be very clear about what that label does and does not mean. HSD is not “EDS lite.” Studies comparing the two groups find a similar burden of symptoms and a similar impact on daily life. In our clinic, HSD and hEDS are managed essentially the same way.

The distinction matters for research and for genetics counseling. It should not change whether you are believed, and it should not change what treatment you are offered.

This is the one that costs people the most years.

The screening tool most doctors use is the Beighton score. It is nine points, checking whether you can bend your pinkies back, pull your thumbs to your forearms, hyperextend your elbows and knees, and place your palms flat on the floor with straight legs. Generally: 5 or more out of 9 counts as generalized hypermobility in an adult, 6 or more in a child before puberty, and 4 or more after about age 50.

Here is the problem. The Beighton score tests five spots on your body, and four of them are in your arms. It says nothing about your hips, your ribs, your jaw, your neck, or your spine. And it is a snapshot — it asks what you can do today, not what you could do at fourteen.

So the person who scores a 2 is regularly told they are not hypermobile, when what has actually happened is one of these:

I wrote a whole piece on this because it comes up so often: I’m Not Flexible — Can I Still Have Hypermobility? For a short clinical summary of the hypermobile subtype itself, see our overview of hypermobile-type EDS.

If connective tissue is everywhere, then a difference in connective tissue shows up everywhere. That is the whole explanation for why your symptom list sounds unbelievable to a doctor who is thinking about one organ at a time.

Dizziness, racing heart, brain fog, fainting. Blood vessels with stretchy walls do not squeeze properly when you stand, so blood pools in your legs and your heart sprints to compensate. This is dysautonomia, and its best-known form is POTS. Start with Understanding the Basics of Dysautonomia, and if your episodes have ever looked like a seizure or a stroke, read POTS, Seizures & Stroke-Like Symptoms.

Flushing, hives, food and medication reactions. Mast cell activation syndrome (MCAS) travels with hypermobility often enough that the three together — hypermobility, dysautonomia, and mast cell problems — have their own nickname in clinic.

Bloating, reflux, constipation, early fullness. Your gut is a muscular tube held together by connective tissue. When the tube is stretchy, it moves food slowly and unpredictably.

Heavy, painful periods and pelvic pain that survives surgery. A pattern that gets mistaken for endometriosis, missed alongside endometriosis, or blamed on endometriosis after the endometriosis is already gone. See Endometriosis, Hypermobility & Pelvic Pain.

Crushing fatigue and poor sleep. Holding an unstable skeleton together all day is real work, and the muscles doing it do not clock out at night. Restless, aching legs are part of this picture too.

Symptoms that started, or exploded, after a virus. A large share of the people arriving in long COVID clinics turn out to have been hypermobile all along. We built an evaluation specifically for that overlap: Long COVID and Hypermobility.

None of these are separate mysteries. They are one material showing up in seven different departments.

If hypermobility were a trendy diagnosis that doctors handed out freely, these numbers would look very different.

Two decades. Ten wrong labels. A 94% chance of being told it was in your head first.

Whatever that is, it is not a diagnosis being handed out too easily. If you have been through some version of that, I would rather you didn’t have to do it again — our directory of hypermobility and EDS specialists exists for exactly that reason.

This is the part of the page I most want you to read, because getting the diagnosis right and then applying standard care anyway is how people get worse in good hands.

Ordinary medicine is built for ordinary connective tissue. Almost every default assumption changes in a hypermobile body.

Patients have reported this for years and been disbelieved for just as long. In a survey of nearly 1,000 people with EDS who had dental work, 88% recalled inadequate numbing, compared with 33% of people without EDS.⁵ A randomized trial published this year confirmed it under controlled conditions: adequate anesthesia thirty minutes after a lidocaine injection in 53% of EDS patients versus 80% of healthy volunteers, with the effect wearing off faster.⁶

Practical version: if you have ever felt a dentist start working before you were numb, you were not imagining it and you were not being dramatic. Tell every proceduralist up front. It changes which agent they reach for and how long they wait.

Tissue that holds stitches poorly, skin that scars widely, joints that can be injured by routine positioning under anesthesia, slower healing, and a higher chance that a repair loosens over time. None of this means you cannot have surgery. It means the team needs to know beforehand. Our surgical and anesthetic precautions guide is written to be printed and handed to your surgeon.

This is the failure I hear about most. A hypermobile patient reports tightness, gets sent to therapy, and is handed a stretching program. It feels wonderful for about twenty minutes. Then everything hurts more.

The tightness was not the problem. The tightness was the solution your body improvised. Those muscles are splinting a joint your ligaments are not holding. Stretch the splint and you hand the instability straight back.

Hypermobile bodies need stabilizing, not lengthening: controlled range, slow progressive loading, real attention to where your joints are in space, and a therapist who understands that “no pain no gain” produces injuries here. That is the entire reason we built a separate physical therapy practice for it — FIT Therapeutics in New Orleans is designed for patients who did not respond to standard PT, and their fascial care pathway lays out how that progression actually works. For hands-on work specifically, see manual fascial therapy.

Strength training is not off the table either — it just has to be loaded intelligently. We wrote up how we do that in safe strength training for hypermobility and EDS.

In a body where the ligaments do not hold, fascia is doing a job it was never designed to do. It thickens, it sticks down, it gets irritated, and it becomes a major source of the deep aching pain that MRI reports call normal.

Standard imaging is not looking for this. We map it with ultrasound in real time, while the patient moves, which is what Fascial Mapping was developed to do. If you want the background on how this field got here, 250 Years of Fascia is a good read.

Standard doses land differently, side effects show up more often, and some of the most useful tools here are ones a general clinic rarely reaches for. Low-dose naltrexone is a good example — a familiar drug used at a fraction of the usual dose for a completely different purpose. Nutrient handling can be different too; I described a folate-related pattern in the peer-reviewed literature, and you can read about it at folate-dependent hypermobility syndrome.

Even the everyday stuff changes. Shoes, braces, hydration, salt, and sleep positioning all matter more in this body type than in any other — our hypermobility tool kit collects the practical ones.

A fifteen-minute appointment cannot evaluate a condition that touches joints, blood pressure, the gut, the immune system, and the nervous system. That mismatch is most of why people bounce between six specialists and end up with six partial answers.

We run a structured, physician-led protocol instead. Across it we cover:

• A full symptom history and timeline — including what your body could do as a teenager
• Hypermobility and EDS screening, Beighton score, and the 2017 criteria
• Fascial Mapping with diagnostic ultrasound to find the tissue actually generating your pain
• Labs, metabolic and genetic testing where it is indicated
• Autonomic screening for POTS and other dysautonomia
• Mast cell, gastrointestinal, and nutritional evaluation
• A written plan you can hand to your other doctors

The full structure is laid out in the Hypermobility & EDS Protocol on our main site, and we coordinate it for out-of-state patients as well as local ones.

If you want proof that this field is being taken seriously rather than drifting in and out of fashion, look at what is happening right now.

The Ehlers-Danlos Society has been running a multi-year international effort called The Road to 2026 to rebuild the classification, the diagnostic criteria, and the care pathways for EDS and hypermobility spectrum disorders. Working groups of clinicians and researchers from around the world have been revisiting everything the 2017 criteria got wrong or left out. The new framework is scheduled to publish on December 1, 2026, in a special issue of the American Journal of Medical Genetics.⁷

Alongside it, the HEDGE study has delivered the clearest genetic picture we have ever had of hypermobile EDS: no single causative gene, a likely combination of many rare variants, and a previously proposed candidate gene ruled out.³ That is not a disappointing result. That is a field maturing in public.

What it means for you: if you were assessed years ago and told you did not qualify, that assessment was made against criteria that are about to be replaced. It is reasonable to be looked at again. And if you do carry a diagnosis, expect the vocabulary around it to shift — that is renaming, not un-diagnosing.

We run this as one program across several sites, because a hypermobile body needs a physician, a therapist, and someone paying attention to the tissue in between.

If you want the deeper science and the medical program — The Fascia Institute and Treatment Center is where the research writing and the full clinical protocol live. Good starting points: hypermobility, EDS, dysautonomia and MCAS care, the five-visit protocol, and our New Orleans hypermobility clinic.

If you are in Southern California — The Fascia Institute and Treatment Center of LA is our Beverly Hills location. See hypermobility and EDS care in Los Angeles, what a hypermobility specialist visit involves, and Fascial Mapping in LA. Our own page for that location is here.

If you need the hands-on therapy side — FIT Therapeutics in the Garden District of New Orleans is the physical therapy practice built for hypermobile patients who did not get better with standard PT. No referral is needed; you can book yourself in.

And if you are still reading and gathering information — the rest of our library is on the hypermobility and EDS blog, with practical handouts in patient resources.

Five things worth keeping.

This is a body type, not a fad. Around 1 in 500 people, not 1 in 5,000. The recognition is new. The people are not.

Loose joints are the symptom, not the condition. The condition is the material — and that material is in your blood vessels, your gut, and your fascia too.

Normal genetic testing does not rule out hypermobile EDS. There is no test for it yet. It is a clinical diagnosis, and careful clinicians get it right.

You do not have to be flexible today. Stiff, guarded, and aching is one of the most common ways a hypermobile body presents, and it is the version most often missed.

The treatment has to be different. Different numbing, different surgical planning, different physical therapy, different dosing. Right diagnosis plus standard care is still the wrong care.

If you have spent years being told your tests are fine while your body clearly is not, there is a reasonable chance nobody has looked at the right tissue yet. That is a fixable problem.

1. Demmler JC, Atkinson MD, Reinhold EJ, et al. Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. BMJ Open. 2019;9(11):e031365.

2. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26.

3. The Ehlers-Danlos Society. HEDGE (Hypermobile Ehlers-Danlos Genetic Evaluation) Study — program updates. 1,000 participants from 86 countries, whole-genome sequencing performed at the Broad Institute.

4. Defining the chronic complexities of hEDS and HSD: a global survey of diagnostic challenges, life-long comorbidities, and unmet needs. J Clin Med. 2025;14(16):5636.

5. Schubart JR, Schaefer E, Janicki P, et al. Resistance to local anesthesia in people with the Ehlers-Danlos syndromes presenting for dental surgery. J Dent Anesth Pain Med. 2019;19(5):261-270.

6. Patients with Ehlers-Danlos syndrome experience reduced effectiveness of lidocaine local anesthetic: a randomized cross-over clinical trial. 2026. PMID 41775498.

7. The Ehlers-Danlos Society. The Road to 2026 — international classification and care pathway update; new framework scheduled for publication December 1, 2026 in a special issue of the American Journal of Medical Genetics.

Medical disclaimer. This article is for learning. It is not medical advice, and it does not replace an evaluation by your own physician. Ehlers-Danlos syndrome and hypermobility spectrum disorder are clinical diagnoses that require an in-person examination. Vascular EDS in particular carries serious risks and should be managed with a geneticist and appropriate specialists. Do not start, stop, or change any medication or treatment based on this article. Seek care promptly for chest pain, severe abdominal pain, fainting, or a sudden change in your symptoms.